WO2023037320 - MUCOSAL MESSENGER RNA VACCINE
National phase entry:
Publication Number
WO/2023/037320
Publication Date
16.03.2023
International Application No.
PCT/IB2022/058528
International Filing Date
09.09.2022
Title **
[English]
MUCOSAL MESSENGER RNA VACCINE
[French]
VACCIN À ARN MESSAGER MUQUEUX
Applicants **
INTRON BIOTECHNOLOGY, INC.
701-704 JungAng Induspia,
137, Sagimakgol-ro, Jungwon-gu
Seongnam-si
Gyeonggi-do 13202, KR
Inventors
YOON, Seong Jun
Daechi-dong, Dongbu Centreville #104-2302, 206, Seolleung-ro Gangnam-gu
Seoul
Seoul 06281, KR
KWON, An Sung
Dopyong-ri, Chowol-eup, Woorim Apt, #204-1202, 119, Hyeonsan-ro
Gwangju-si
Gyeonggi-do 12793, KR
JUN, Soo Youn
Jamwon-dong, Laemian Sinbanpo palace Apt, #103-902, 35, Jamwon-ro 8 Gil, Seocho-gu
Seoul
Seoul 06518, KR
PARK, Ji Sung
Unjung-dong, Kunyoung LIG Apt, #401-2101, 7, Pangyowon-ro, Bundang-gu
Seongnam-si
Gyeonggi-do 13464, KR
PARK, Seon Ho
Jayang-dong, #302, 50-3, Ttukseom-ro 52ra-gil, Gwangjin-gu
Seoul
Seoul 05101, KR
KANG, Sang Hyeon
Jams il-dong, Jamsil els Apt.# 140-1602, 99, Olympic-ro Songpa-gu
Seoul
Seoul 05501, KR
Priority Data
63/243,086
10.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 964 | |
| EPO | Filing, Examination | 6427 | |
| Japan | Filing | 593 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 11269 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention is related to a mucosal mRNA vaccine. More specifically, the present invention relates to novel mucosal mRNA vaccine based on a peptide-conjugated, mRNA loaded nanoparticle with enhanced vaccine efficacy, and a method of preparing the same.[French]
La présente invention concerne un vaccin à base d'ARNm muqueux. Plus spécifiquement, la présente invention concerne un nouveau vaccin d'ARNm muqueux basé sur une nanoparticule chargée d'ARNm conjugué à un peptide ayant une efficacité de vaccin améliorée et un procédé de préparation de celui-ci.